Eléments de l'association
|
List of bibliographic references
Number of relevant bibliographic references: 3.Ident. | Authors (with country if any) | Title |
---|---|---|
005260 | D. C. Talbot [Royaume-Uni] ; V. Moiseyenko [Russie] ; S. Van Belle [Belgique] ; S. M. O'Reilly [Royaume-Uni] ; E. Alba Conejo [Espagne] ; S. Ackland [Australie] ; P. Eisenberg [États-Unis] ; D. Melnychuk [Canada] ; T. Pienkowski [Pologne] ; H-U Burger [Suisse] ; S. Laws [France] ; B. Osterwalder [Suisse] | Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines |
005423 | J. Cassidy [Royaume-Uni] ; C. Twelves [Royaume-Uni] ; E. Van Cutsem [Belgique] ; P. Hoff [États-Unis] ; E. Bajetta [Italie] ; M. Boyer [Australie] ; R. Bugat [France] ; U. Burger [Suisse] ; A. Garin [Russie] ; U. Graeven [Allemagne] ; J. Mckendrick ; J. Maroun ; J. Marshall ; B. Osterwalder [Suisse] ; G. Perez-Manga ; R. Rosso ; P. Rougier ; R. L. Schilsky | First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin |
005727 | J. A. O'Shaughnessy [États-Unis] ; J. Blum [États-Unis] ; V. Moiseyenko [Russie] ; S. E. Jones [États-Unis] ; D. Miles [Royaume-Uni] ; D. Bell [Australie] ; R. Rosso [Italie] ; L. Mauriac [France] ; B. Osterwalder [Suisse] ; H.-U. Burger [Suisse] ; S. Laws [France] | Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer |
This area was generated with Dilib version V0.6.33. |